search
Back to results

Dexamethasone for Paediatric Adeno-tonsillectomy - A Dose-finding Study

Primary Purpose

Postoperative Nausea and Vomiting, Postoperative Pain

Status
Terminated
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
dexamethasone
Dexamethasone
dexamethasone
Saline
Sponsored by
University Hospital, Geneva
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Postoperative Nausea and Vomiting focused on measuring Adenotonsillectomy, Pediatrics, Postoperative Nausea and Vomiting, Pain, Oral intake, Dexamethasone, Dose finding

Eligibility Criteria

3 Years - 16 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  • Elective tonsillectomy with or without adenoidectomy with or without eartubes

Exclusion criteria:

  • ASA > II
  • Allergie to Dexamethasone
  • Recent therapy with steroids or immunotherapy
  • Mental retardation
  • Children experiencing nausea or vomiting or have taken antiemetic medication within 24 hours before surgery
  • Additional surgery
  • Enrolement in another investigational study
  • Chronic infection or diabetes
  • Recent vaccination (less than 1 month prior to surgery)
  • Recent varicella infection (less than 1 month prior to surgery)

Sites / Locations

  • University Hospital of Geneva, Anesthesia Department

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

1

2

3

4

Arm Description

Intravenous dexamethasone 0.05 mg per kg bodyweight

Intravenous dexamethasone 0.15 mg per kg bodyweight

Intravenous dexamethasone 0.5 mg per kg bodyweight

Intravenous saline

Outcomes

Primary Outcome Measures

Investigation of the dose-effect relationship of prophylactic single-dose dexamethasone for the prevention of postoperative nausea and vomiting in children undergoing adeno-tonsillectomy

Secondary Outcome Measures

Dose-effect relationship for the prevention of postoperative pain
Oral intake
Effect on general outcome
Investigation of safety (drug-related harm)

Full Information

First Posted
November 24, 2006
Last Updated
August 13, 2010
Sponsor
University Hospital, Geneva
search

1. Study Identification

Unique Protocol Identification Number
NCT00403806
Brief Title
Dexamethasone for Paediatric Adeno-tonsillectomy - A Dose-finding Study
Official Title
Antiemetic and Analgesic Efficacy and Safety of Dexamethasone for Paediatric Adeno-tonsillectomy - A Randomised, Placebo-controlled, Double-blind, Dose-finding Study
Study Type
Interventional

2. Study Status

Record Verification Date
January 2009
Overall Recruitment Status
Terminated
Why Stopped
drug-related harm
Study Start Date
February 2005 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
December 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University Hospital, Geneva

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Adeno-tonsillectomy is a commonly performed surgical procedure in children. Main morbidities are postoperative pain, nausea and vomiting, and haemorrhage. Non-steroidal anti-inflammatory drugs (NSAIDs)widely used for paincontrol increase the risk of postoperative bleeding and reoperation. Dexamethasone is an powerful antiemetic and has shown analgesic efficacy. Antiemetic and analgesic dose-response has never been established.
Detailed Description
Primary objective: To investigate the dose-effect relationship of prophylactic single-dose dexamethasone for the prevention of PONV in children undergoing adeno-tonsillectomy. Secondary objective:To investigate the dose-effect relationship of prophylactic single-dose dexamethasone for the prevention of postoperative pain and its effect on general outcome in children undergoing adeno-tonsillectomy. To investigate the safety of dexamethasone in children undergoing adeno-tonsillectomy. Study Population:Children, aged 3 to 16 years, scheduled for elective tonsillectomy with or without adenoidectomy, and with or without ear tubes will be included. Children will stay the first postoperative night at the hospital and will be discharged the day after surgery. Randomisation and blinding:Children will be randomised to one of four groups of equal size: Group 1: Placebo NaCL 0.9%,Group 2:Dexa 0.05 mg/kg, Group 3: Dexa 0.15 mg/kg, Group 4:Dexa 0.5 mg/kg Indistinguishable 20 ml ampoules will be prepared and randomised by the Hospital Pharmacy. Children will receive 0.5 ml/kg of the solution as an IV bolus after induction of anaesthesia. The maximum volume of dexamethasone injected will be limited to 20 ml (corresponding to a maximum dose of 20 mg in a child with ≥40 kg bodyweight). Standardized Anesthesia technique and surgical procedure Variables measured 5.1. Intraoperatively Type of surgery Surgical time Dose of opioid 5.2. Postoperatively Follow up will be during the hospital stay, through a telephone interview 48 hours after surgery, and through a surgical control (standard procedure) at about one week. Preoperatively, parents and children will be instructed in the evaluation of pain. Parents will be given a questionnaire to be filled in twice daily (morning and evening) after discharge of the child, and to bring it back to the routine postoperative surgical control at one week (or to send it back by post). Endpoint PONV Cumulative incidence of vomiting (including retching) during the first 6 postoperative hours. Cumulative incidence of nausea during the first 6 postoperative hours. Nausea is only recorded if the child is able to express the sensation of nausea. Cumulative incidence of vomiting (including retching) during the first 24 postoperative hours. Cumulative incidence of nausea during the first 24 postoperative hours. Rescue medication for PONV is with ondansetron (Zofran) 50 µg/kg IV or droperidol 20 µg/kg IV. Rescue antiemesis will be recorded. Endpoint pain intensity In hospitalised children, pain assessment will be with the revised Faces Pain Scale (FPS-r) [Hicks et al, 2001] and with the conventional 0-10 cm Visual Analogue Scale (VAS). The FPS-r was adapted from the Faces Pain Scale [Bieri et al, 1990] in order to make it possible to score on the widely accepted 0-10 point metric. It shows a close linear relationship with the visual analogue pain scale across the age range from 4 to 16 years. In the case that a younger child is not able to express adequately its pain with the FPS-r or with the VAS we will use the CHEOP Scale (Children of Eastern Ontario Pain Scale); this is a behavioural observation scale [McGrath et al,1985]. Pain will be evaluated at arriving in the PACU, 1-hourly during the PACU stay, 4-hourly on the ward, and twice daily after discharge (see questionnaire). Sleeping children will not be woken up. Cumulative doses per day of paracetamol/codeine and of any other analgesic (NSAIDs, opioids) will be recorded. Further endpoints Quality of sleep during each the night until the surgical visit. Each morning, the care-giver (nurse, parent) will estimate the child's quality of sleep on a NRS ranging from 0=did not sleep at all to 10=excellent sleep. First oral intake of fluid (including ice cream); hours after end of surgery. First oral intake of solid food; hours after end of surgery. At discharge: Overall "satisfaction" judged by the nurse on a NRS ranging from 0=not satisfied at all to 10=very much satisfied. Degree of stress on the part of the parents due to the child's "illness". Rated by the parents on a daily basis on a NRS scale from 0=not stressed at all to 10=very much stressed. At the surgical visit: Overall "satisfaction" judged by the parents on a NRS ranging from 0=not satisfied at all to 10=very much satisfied. Adverse effects, safety Any minor complication: definition: no need for readmission. Any major complication: definition: does need readmission (for instance, readmission due to bleeding, re-operation due to bleeding).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Nausea and Vomiting, Postoperative Pain
Keywords
Adenotonsillectomy, Pediatrics, Postoperative Nausea and Vomiting, Pain, Oral intake, Dexamethasone, Dose finding

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
215 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Intravenous dexamethasone 0.05 mg per kg bodyweight
Arm Title
2
Arm Type
Active Comparator
Arm Description
Intravenous dexamethasone 0.15 mg per kg bodyweight
Arm Title
3
Arm Type
Active Comparator
Arm Description
Intravenous dexamethasone 0.5 mg per kg bodyweight
Arm Title
4
Arm Type
Placebo Comparator
Arm Description
Intravenous saline
Intervention Type
Drug
Intervention Name(s)
dexamethasone
Other Intervention Name(s)
Mephamesone
Intervention Description
intravenous dexamethasone 0.05 mg per kg bodyweight
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Other Intervention Name(s)
mephamesone
Intervention Description
Intravenous dexamethasone 0.15 mg per kg bodyweight
Intervention Type
Drug
Intervention Name(s)
dexamethasone
Other Intervention Name(s)
mephamesone
Intervention Description
Intravenous dexamethasone 0.5 mg per kg bodyweight
Intervention Type
Drug
Intervention Name(s)
Saline
Other Intervention Name(s)
mephamesone
Intervention Description
Intravenous saline
Primary Outcome Measure Information:
Title
Investigation of the dose-effect relationship of prophylactic single-dose dexamethasone for the prevention of postoperative nausea and vomiting in children undergoing adeno-tonsillectomy
Time Frame
24 hours postoperatively
Secondary Outcome Measure Information:
Title
Dose-effect relationship for the prevention of postoperative pain
Time Frame
24 hours postoperatively
Title
Oral intake
Time Frame
10 days
Title
Effect on general outcome
Time Frame
10 days
Title
Investigation of safety (drug-related harm)
Time Frame
10 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: Elective tonsillectomy with or without adenoidectomy with or without eartubes Exclusion criteria: ASA > II Allergie to Dexamethasone Recent therapy with steroids or immunotherapy Mental retardation Children experiencing nausea or vomiting or have taken antiemetic medication within 24 hours before surgery Additional surgery Enrolement in another investigational study Chronic infection or diabetes Recent vaccination (less than 1 month prior to surgery) Recent varicella infection (less than 1 month prior to surgery)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christoph A Czarnetzki, MD, MBA
Organizational Affiliation
anesthesia department
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Martin Tramer, MD, PhD
Organizational Affiliation
anesthesia department
Official's Role
Study Chair
Facility Information:
Facility Name
University Hospital of Geneva, Anesthesia Department
City
Geneva
State/Province
Canton of Geneva
ZIP/Postal Code
1211
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
19066382
Citation
Czarnetzki C, Elia N, Lysakowski C, Dumont L, Landis BN, Giger R, Dulguerov P, Desmeules J, Tramer MR. Dexamethasone and risk of nausea and vomiting and postoperative bleeding after tonsillectomy in children: a randomized trial. JAMA. 2008 Dec 10;300(22):2621-30. doi: 10.1001/jama.2008.794.
Results Reference
result

Learn more about this trial

Dexamethasone for Paediatric Adeno-tonsillectomy - A Dose-finding Study

We'll reach out to this number within 24 hrs